Compare Twist Bioscience Corp (TWST) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Verisign, Inc. — how do they compare? Twist Bioscience Corp trades at $88.31 (market cap $5.45B), while Verisign, Inc. trades at $268.94 (market cap $25.26B). The key difference: Verisign, Inc. is far larger — about 4.6× Twist Bioscience Corp's market cap, and Verisign, Inc. pays a 1.17% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | VRSN | |
|---|---|---|
Market Cap | $5.45B | $25.26B |
Sector | Health | Technology |
52-Week High | $102.88 | $310.00 |
52-Week Low | $24.16 | $211.49 |
Enterprise Value | $5.37B | $26.50B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
VeriSign (VRSN) trades at $266.15, down 4.15% over the past day, with a mixed technical outlook showing bullish moving averages but overbought oscillators. The company maintains strong fundamentals with 2025 revenue of $1.66 billion, net income of $825.7 million, and a robust net income margin of 49.96%. Recent Q1 2026 earnings beat expectations with EPS of $2.34, while Q2 2026 results are anticipated. Analyst sentiment is predominantly positive with a 57% buy rating and a consensus price target of $325.25, suggesting significant upside potential.
The outlook for VRSN is cautiously optimistic, driven by its monopoly position in .com and .net domain registrations, consistent cash flow generation, and potential tailwinds from AI-driven domain growth. Key risks include contract renewal uncertainties, competitive pressures, and high valuation multiples. Investors should weigh the stock's premium valuation against its stable revenue streams and growth catalysts from digital expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
